Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 11/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CLCN2 | P51788 | 2/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17616659 | 0.89 | MRGPRX4 (0.52) | MRGPRX4TP53HTTFOLH1ALDH1A1 | |
| SCHEMBL16273652 | 0.88 | TP53 (0.53) | MRGPRX4TP53HTTFOLH1ALDH1A1 | |
| SCHEMBL17616648 | 0.85 | MRGPRX4 (0.54) | MRGPRX4TP53HTTFOLH1ALDH1A1 | |
| SCHEMBL16273613 | 0.83 | MRGPRX4 (0.52) | MRGPRX4TP53HTTFOLH1ALDH1A1 | |
| SCHEMBL24677896 | 0.82 | MRGPRX4 (0.51) | MRGPRX4TP53HTTFOLH1ALDH1A1 | |
| SCHEMBL29831705 | 0.82 | MRGPRX4 (0.51) | MRGPRX4TP53HTTFOLH1ALDH1A1 | |
| SCHEMBL5291219 | 0.80 | HTT (0.68) | MRGPRX4TP53HTTFOLH1ALDH1A1 | |
| SCHEMBL2451531 | 0.80 | ALDH1A1 (0.59) | MRGPRX4TP53HTTFOLH1ALDH1A1 | |
| SCHEMBL17616617 | 0.78 | MRGPRX4 (0.55) | MRGPRX4TP53HTTFOLH1ALDH1A1 | |
| SCHEMBL17804521 | 0.78 | MRGPRX4 (0.59) | MRGPRX4TP53HTTFOLH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9675072-B2 | Tetrazolinone compound and application of same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-06-13 | — | — | US | disclosed |
| US-9512090-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-12-06 | — | — | US | disclosed |
| US-20160159755-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| US-20160081340-A1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159755-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | CYP1A1, CASP1, TCOF1 | MRGPRX4 1910/4885TP53 3591/4885HTT 1597/4885 |
| US-20160081340-A1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | CYP2E1, MT-CO2, CASP3 | MRGPRX4 2185/4885TP53 3963/4885HTT 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.